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Leeds, England; Torrance and Los Angeles, California; Bern, Switzerland; and Graz, AustriaObjectives This study sought to identify nonredundant atrial ﬁbrillation (AF) genetic susceptibility signals and examine their
cumulative relations with AF risk.Background AF-associated loci span broad genomic regions that may contain multiple susceptibility signals. Whether multiple
signals exist at AF loci has not been systematically explored.Methods We performed association testing conditioned on the most signiﬁcant, independently associated genetic markers at
9 established AF loci using 2 complementary techniques in 64,683 individuals of European ancestry (3,869 incident
and 3,302 prevalent AF cases). Genetic risk scores were created and tested for association with AF in Europeans
and an independent sample of 11,309 individuals of Japanese ancestry (7,916 prevalent AF cases).Results We observed at least 4 distinct AF susceptibility signals on chromosome 4q25 upstream of PITX2, but not at the
remaining 8 AF loci. A multilocus score comprised 12 genetic markers demonstrated an estimated 5-fold gradient in
AF risk. We observed a similar spectrum of risk associated with these markers in Japanese. Regions containing AF
signals on chromosome 4q25 displayed a greater degree of evolutionary conservation than the remainder of the
locus, suggesting that they may tag regulatory elements.
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1202stratiﬁcation of individuals accor-
ding to genetic risk for arrhythmia.See page 1211We sought to determine
whether additional AF suscepti-
bility signals exist within locipreviously identiﬁed in genome-wide association studies of
AF among participants of European ancestry within the
AFGen Consortium (12). We then sought to determine
whether our observations regarding AF-associated genetic
variants are generalizable in an independent sample of Jap-
anese ancestry.Methods
Study participants. We included subjects of European
ancestry from 8 prospective cohort and 12 case-control study
samples derived from the AGES (Age, Gene/Environment
Susceptibility) Reykjavik Study, ARIC (Atherosclerosis Risk
in Communities), CCAF (Cleveland Clinic Lone AF
GeneBank Study), CHS (Cardiovascular Health Study)
study, FHS (Framingham Heart Study), AFNET/KORA
(German Competence Network for Atrial Fibrillation/
Cooperative Research in the Region of Augsburg) study,
LURIC (Ludwigshafen Risk and Cardiovascular Health
Study), MGH (Massachusetts General Hospital Atrial
Fibrillation Study), HVH (Heart and Vascular Health
Study), PHASE/PROSPER (PHArmacogenetic study of
Statins in the Elderly at risk/PROspective Study of Pra-
vastatin in the Elderly at Risk for vascular disease) study,
RS-I and RS-II (Rotterdam Study I and II) studies, SHIP
(Study of Health in Pomerania) study, and WGHS
(Women’s Genome Health Study). Validation of our ﬁnd-
ings was performed in the BioBank Japan case-control
sample. Brief summaries of each study are provided in the
Appendix. The Institutional Review Boards at each of the
respective studies approved all of the studies. Study partic-
ipants provided written informed consent to participate in
genetic research.
AF ascertainment. In each study, AF was ascertained from
electrocardiograms, Holter recordings, medical records, or
hospital discharge diagnostic codes (ICD-8 427.92; ICD-
9-CM 427.3, 427.31, or 427.32; or ICD-10 I48 in any
position), as previously described (13–19). AF was consid-
ered prevalent if ascertained in case-control studies or if it
was present at or prior to DNA collection in cohort studies.
Incident AF was deﬁned if it occurred after DNA collection
in participants without a history of AF. In the ARIC study,
the baseline examination was used rather than DNA
collection for these deﬁnitions and follow-up.
Genotyping. Genome-wide genotyping for array-speciﬁc
single nucleotide polymorphisms (SNPs) was conducted in
each study as previously described (12). Imputation wasperformed for up to 2.2 million autosomal SNPs on the basis
of the HapMap CEU panel (20). For the AFNET/KORA
study, the SNP rs12235316_G was substituted for
rs10821415_A (distance w40 kilobases [kb], r2 ¼ 1) on
chromosome 9q22 as this SNP was unavailable on the basis
of the study’s imputation. Details regarding genotyping
platforms, quality control metrics, and imputation methods
are provided in Online Table 1.
Statistical analysis. We deﬁned AF loci a priori as the
genomic region centered on the most signiﬁcantly associated
SNP from a prior meta-analysis (12) and ﬂanked by 1 mega-
base (Mb) on either side. To determine whether multiple
associated signals for AF exist beyond the top associated
variant at each AF associated locus, we employed 2 different
conditional analysis approaches.
First, we performed a traditional conditional analysis, in
which we iteratively repeated association testing within each
genome-wide signiﬁcant locus with adjustment for the most
signiﬁcantly associated genome-wide association signal
(p < 5  10–8) remaining at the locus in each cohort, until
no further genome-wide signiﬁcant SNPs remained.
Because we previously identiﬁed a total of 3 distinct sus-
ceptibility signals at the chromosome 4q25 locus, we
adjusted for the genotypes of SNPs tagging these signals
(rs6817105, a perfect proxy for a previously reported signal
rs2200733; rs17570669; and rs3853445) when performing
association testing on chromosome 4q25 (21). At all other
loci, we began the iterative association testing process by
adjusting for the single most signiﬁcantly associated SNP at
the locus. Study-speciﬁc effect estimates were combined via
meta-analyses as described subsequently.
Second, as an alternative method of discovery, we
employed an approximate conditional analysis to estimate
nonredundant signals directly from the summary statistics of
a prior genome-wide meta-analysis (12) using the GCTA
software package (22). Linkage disequilibrium and allele
frequencies were estimated from 2,058 unrelated individuals
from the FHS study. Potential nonredundant signals iden-
tiﬁed were then tested for association with AF in each study
cohort, and the study-speciﬁc effect estimates were com-
bined by meta-analyses.
For each approach we examined study-speciﬁc associa-
tions between SNPs and AF using logistic regression for
prevalent AF, and proportional hazards regression for inci-
dent AF. In the FHS study, we used generalized estimating
equations with an independence working correlation struc-
ture in a logistic model for prevalent AF, as implemented
in the geepack package in R (23) and robust variance esti-
mators (clustering on family) in a Cox model for incident
AF as implemented in the survival package in R (24) to
account for potential relatedness among participants. All
models were ﬁtted assuming additive genetic effects for
each SNP (i.e., multiplicative relative risks). Age at DNA
collection (or baseline for the ARIC study), sex, and prin-
cipal components of ancestry signiﬁcantly associated with
AF were included in the models.
Table 1 Participating Study Characteristics
Participants AF
Age,*
yrs
Age Range,*
yrs Male Hypertension
European ancestry
Incident AF
AGES 2,718 158 76.5  5.5 66–95 1,154 (39.0) 2,595 (87.7)
ARIC 8,890 802 54.3  5.7 44–66 4,181 (47.0) 2,376 (26.7)
CHS 3,204 764 72.2  5.3 65–98 1,242 (38.8) 1,678 (52.4)
FHS 4,062 310 64.7  12.6 31–101 1,771 (43.6) 2,001 (49.3)
PROSPER 5,244 505 75.3  3.4 69–83 2,525 (48.1) 3,257 (62.1)
RS-I 5,665 542 69.1  9.0 55–99 2,282 (40.3) 1,866 (32.9)
RS-II 1,739 65 64.8  7.9 55–95 795 (45.7) 600 (34.5)
WGHS 20,843 723 54.1  7.0 43–89 0 5,022 (24.1)
Prevalent AF
AFNET/KORA Cases 468 51.8  7.2 29–74 236 (50.4) 252 (53.8)
Controls 438 56.2  7.1 45–69 219 (50.0) 185 (42.2)
AGES Cases 241 78.5  5.9 67–95 88 (55.7) 143 (90.5)
Controls 2,718 76.1  5.4 66–94 70 (36.1) 2,002 (78.2)
CCAF Cases 496 58.8  10.7 20–84 375 (75.6) 269 (54.2)
Controls 2,971 28.5  22.2 0–87 1,124 (37.8) d
HVH Cases 95 59.5  6.5 40–68 28 (29.5) 50 (52.6)
Controls 193 59.5  6.0 40–69 106 (54.9) 153 (79.3)
CHS Cases 67 76.3  5.8 66–90 38 (56.7) 35 (52.2)
Controls 3,204 72.2  5.3 65–98 1,242 (38.8) 1,678 (52.4)
FHS Cases 253 76.9  9.9 45–97 151 (59.7) 180 (71.1)
Controls 4,151 64.7  12.6 31–101 1,807 (43.5) 2,036 (49.1)
LURIC Cases 361 66.4  9.2 32–88 258 (71.7) 269 (74.5)
Controls 2,598 62.2  10.7 17–92 1,819 (70.0) 1,885 (72.6)
MGH/MIGEN Cases 366 53.4  10.5 21–77 295 (80.6) 85.8 (22.7)
Controls 911 47.9  8.8 18–83 485 (53.2) d
RS-I Cases 309 76.2  8.7 56–98 145 (46.9) 131 (42.4)
Controls 5,665 69.1  9.0 55–99 2,282 (40.3) 1,866 (32.9)
RS-II Cases 66 73.9  9.5 56–95 35 (53.0) 35 (53.0)
Controls 1,739 64.8  7.9 55–95 795 (45.7) 600 (34.5)
SHIP Cases 107 65.1  11.5 21–81 69 (64.5) 59 (55.1)
Controls 1,816 50.7  14.9 21–81 906 (49.9) 437 (24.1)
WGHS Cases 473 56.2  7.8 45–85 0 152 (32.2)
Controls 20,843 54.1  7.0 43–89 0 5,022 (24.1)
Japanese
Prevalent AF
BioBank Japan Cases 7,916 68.2  10.3 19–100 5,545 (70.1) 5,655 (71.4)
Controls 3,393 51.6  16.6 3–96 1,853 (54.6) 1,160 (34.2)
Values are n, mean  SD, or n (%). *Age at DNA collection (or baseline for the ARIC [Atherosclerosis Risk in Communities] study).
AF ¼ atrial ﬁbrillation; AFNET/KORA ¼ German Competence Network for Atrial Fibrillation/Cooperative Research in the Region of Augsburg;
AGES ¼ Age, Gene/Environment Susceptibility; ARIC ¼ Atherosclerosis Risk in Communities; CHS ¼ Cardiovascular Health Study; FHS ¼ Framingham
Heart Study; HVH ¼ Heart and Vascular Health Study; LURIC ¼ LURIC (Ludwigshafen Risk and Cardiovascular Health Study; MGH/MIGEN ¼ Mas-
sachusetts General Hospital Atrial Fibrillation Study/Myocardial Infarction Genetics Consortium; PROSPER ¼ PROspective Study of Pravastatin in the
Elderly at Risk for vascular disease; RS ¼ Rotterdam Study; SHIP ¼ Study of Health in Pomerania; WGHS ¼ Women’s Genome Health Study.
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1203For all analyses, study-speciﬁc regression estimates were
meta-analyzed using an inverse variance weighted method.
Prevalent and incident AF were meta-analyzed together
as previously performed (10,12). We considered a 2-sided
p < 5  10–8 to provide signiﬁcant evidence for inde-
pendent associations between SNPs and AF. We consid-
ered a 2-sided p  1  10–7 to provide suggestive evidence
of association. We calculated linkage disequilibrium met-
rics (r2, D’) for all AF associated variants in the same
region.Because the 2 conditional analysis approaches yielded
similar results (see subsequent results), when different SNPs
identiﬁed from the 2 different approaches at a given locus
were in linkage disequilibrium with one another, we selected
the SNP with the smaller p value for further modeling. We
then ﬁt multi-SNP models that included each of the selected
nonredundant SNPs to examine adjusted SNP associations
with AF.
We constructed both unweighted and weighted multi-
marker genetic risk scores with the selected independent AF
Lubitz et al. JACC Vol. 63, No. 12, 2014
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1204susceptibility signals by summing the dosages of AF risk
SNPs. In weighted scores, we multiplied the allele dosages
for each individual by SNP-speciﬁc regression coefﬁcient
estimates derived from either the conditional analysis (for
SNPs on chromosome 4q25) or a prior meta-analysis (for
the remaining SNPs) (12). Unweighted scores were the sum
of dosages for all SNPs included in the score.
We hypothesized that SNPs contribute additively to AF
risk and therefore tested the associations between an
aggregate multimarker panel of risk alleles and AF. We
constructed multimarker scores for the chromosome 4q25
locus alone as well as across all AF-associated loci. We
included a total of 4 nonredundant SNPs from chromosome
4q25 and 8 from the remaining loci (see subsequent results);
therefore, the total number of AF risk alleles ranged from
0 to 8 at the chromosome 4q25 locus and from 0 to 24 across
all loci. We created 8 categories for multimarker scores at the
chromosome 4q25 locus, reﬂecting each of the estimated
number of risk alleles. For scores across all loci, we created 12
potential categories, each reﬂecting increments of 2Figure 1 Genome-Wide and Conditional Associations Between Genet
Associations between genetic variants and atrial ﬁbrillation are displayed (A) across the
(B) at each genome-wide signiﬁcant susceptibility locus after adjustment for the genotypestimated AF risk alleles, in order to avoid rare and inesti-
mable categories of risk alleles that might occur with single
risk allele increments. For weighted multimarker risk scores,
10 categories were selected on the basis of cutoff values used
to derive score deciles in the MGH sample (Online Table 2).
In order to determine whether observed associations were
generalizable beyond individuals of European ancestry, we
performed association testing in the independent BioBank
Japan sample using the same statistical methodology
described above.
We examined whether nonredundant signals at the
chromosome 4q25 locus were more likely to be evolution-
arily conserved than the rest of the locus by comparing
sequence alignments in 44 vertebrate species. We compared
the average phylogenetic conservation scores between 10 kb
regions centered on each of the nonredundant signals on
chromosome 4q25 to that of the rest of the 1 Mb locus using
the Student t test (see Online Appendix for details).
In order to examine the relations between identiﬁed ge-
netic variants and prognosis, we assessed the relationsic Variants and Atrial Fibrillation
genome in marginal association analyses as previously reported (12) and
e of the most signiﬁcantly associated single nucleotide polymorphism at that locus.
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1205between nonredundant AF-associated SNPs and both sur-
vival and survival free of major disease or mortality on the
basis of a prior genome-wide association study of aging in
individuals of European ancestry (25). Brieﬂy, the analysis
was performed by examining associations between SNPs and
time to incident disease or death in 25,007 individuals older
than 55 years of age. Associations were modeled using
proportional hazards regression with time since DNA
collection as the time scale, with adjustment for age at DNA
collection and sex. Survival free of major disease or mortality
was modeled by using time to death or to the ﬁrst
myocardial infarction, heart failure, stroke, dementia, hip
fracture, or cancer diagnosis. Participants with any of the
modeled outcomes at baseline were excluded from the
analysis.Results
Characteristics of participants in the included studies are
provided in Table 1. Overall, the analysis included a total of
64,683 individuals of European ancestry, including 3,302
individuals with prevalent AF and 3,869 individuals with
incident AF.
We observed evidence for multiple genome-wide signiﬁ-
cant AF susceptibility signals on chromosome 4q25, but
no independent signals beyond the ﬁrst at the remaining 8
AF-associated loci (Fig. 1). With the traditional conditional
analysis approach, we identiﬁed 2 potential signals associated
with AF (rs2723288 and rs4400058) with p < 5  10–8
after simultaneous adjustment for previously reported signals
(rs6817105, rs17570669, and rs3853445). After including
rs2723288, rs6817105, rs4400058, rs17570669, and
rs3853445 in a model, rs6817105 (p ¼ 1.1  10–85) and
rs4400058 (p ¼ 2.2  10–16) remained signiﬁcantly asso-
ciated with AF (Table 2). One of the previously reported
(21) signals (rs3853445, p ¼ 1.0  10–7) remained sug-
gestive of association whereas another was not associatedTable 2 Results of Conditional Analysis at the Chromosome 4q25 Lo
SNP
AF Risk /
Referent Allele
Chr 4q25 HG19
Position
AF Risk Allele
Frequency
Traditional conditional analysis
rs2723288y A / C 111581402 0.30
rs6817105z C / T 111705768 0.14
rs4400058y A / G 111716673 0.09
rs17570669 A / T 111736882 0.92
rs3853445y T / C 111761487 0.74
Approximate conditional analysis
rs1448818y C / A 111570223 0.25
rs6817105z C / T 111705768 0.14
rs4032974y C / T 111732536 0.09
rs6838973y C / T 111765495 0.44
All models adjusted for age, sex and signiﬁcant principal components of ancestry. rs6817105, r
susceptibility signals and were forced into the traditional conditional analysis model. *Discovery dat
nucleotide polymorphism (SNP).
CI ¼ conﬁdence interval; RR ¼ relative risk.with AF at the pre-speciﬁed genome-wide signiﬁcance
threshold (rs17570669, p¼ 5.2 10–3). Notably, rs17570669
had a low imputation quality score in 2 studies (the HVH
and CHS studies; R2 ¼ 0.12 and 0.18, respectively), and
had imputation quality less than 0.8 in several others (the
SHIP, RS-I, AGES, CCAF, WGHS, AFNET, and FHS
studies), which may have affected the association signal.
Nevertheless, we did not include it in subsequent multimarker
analyses given the lack of genome-wide signiﬁcant association
that was observed in the adjusted association analyses.
In the approximate conditional analysis approach, we
identiﬁed 4 potential signals at the chromosome 4q25 locus,
tagged by SNPs rs1448818, rs6817105, rs4032974, and
rs6838973 (Table 2). In models in which we adjusted for all
4 potential SNPs, rs1448818 (p ¼ 1.6  10–8), rs6817105
(p ¼ 5.1  10–95), and rs6838973 (p ¼ 6.0  10–9)
remained signiﬁcantly associated with AF. Results from the
traditional conditional analysis and approximate conditional
analysis were similar to one another in that the signiﬁcantly
associated signals were in linkage disequilibrium with one
another (Table 2, Online Table 3).
When different SNPs identiﬁed from the 2 different
approaches at a given locus were in linkage disequilibrium
with one another, we selected the SNP with the smallest
p value from either approach for further modeling
(rs1448818, rs6817105, rs4400058, rs6838973). We
examined adjusted SNP associations with AF by meta-
analyzing results from cohort-speciﬁc models that included
all of the selected nonredundant SNPs on chromosome
4q25 alone, as well as across all loci (Table 3). We observed
persistent genome-wide association between the selected
nonredundant chromosome 4q25 SNPs and AF, but
attenuation of associations at some of the other loci that was
most pronounced for the chromosome 7q31 locus
(rs3807989, p ¼ 6.3  10–3).
The identiﬁed signals on chromosome 4q25 span a 195 kb
intergenic region (Fig. 2, Online Fig. 1). The newly identiﬁedcus in the AFGen Consortium
Marginal Association* Conditional Association
RR (95% CI) p Value RR (95% CI) p Value
1.16 (1.11–1.21) 5.3  10–12 1.06 (1.03–1.09) 1.4  10–4
1.64 (1.55–1.73) 1.8  10–74 1.62 (1.54–1.70) 1.1  10–85
1.18 (1.11–1.26) 1.1  10–7 1.28 (1.21–1.36) 2.2  10–16
1.14 (1.04–1.23) 5.1  10–3 1.06 (1.02–1.12) 5.2  10–3
1.23 (1.18–1.28) 1.8  10–19 1.12 (1.08–1.18) 1.0  10–7
1.14 (1.09–1.19) 7.3  10–9 1.12 (1.08–1.17) 1.6  10–8
1.64 (1.55–1.73) 1.8  10–74 1.58 (1.50–1.65) 5.1  10–95
1.20 (1.12–1.28) 2.6  10–8 1.07 (1.03–1.11) 1.5  10–3
1.20 (1.16–1.27) 8.8  10–20 1.11 (1.08–1.15) 6.0  10–9
s17570669, and rs3853445 have previously been reported as distinct atrial ﬁbrillation (AF)
a from Ellinor et al. (12). yn linkage disequilibrium with one another (r2 >0.3). zSame single
Table 3
Marginal and SNP-Adjusted Associations Between Distinct AF Susceptibility SNPs and AF in the AFGen Consortium and
BioBank Japan Sample
SNP
Chromosomal
Locus
AF Risk /
Referent Allele
AFGen
Marginal Analysis*
SNP Adjusted
Chromosome 4q25 Onlyy
AF Risk Allele
Frequency* RR (95% CI) p Value RR (95% CI) p Value
rs6666258 1q21 /KCNN3-PMVK C / G 0.30 1.18 (1.13–1.23) 2.0  10–14 d d
rs3903239 1q24 / PRRX1 G / A 0.45 1.14 (1.10–1.18) 9.1  10–11 d d
rs1448818 4q25 / PITX2 C / A 0.25 1.14 (1.09–1.19) 7.3  10–9 1.12 (1.08–1.17) 2.0  10–8
rs6817105 4q25 / PITX2 C / T 0.13 1.64 (1.55–1.73) 1.8  10–74 1.56 (1.49–1.64) 3.3  10–74
rs4400058 4q25 / PITX2 A / G 0.10 1.18 (1.11–1.26) 1.1  10–07 1.33 (1.26–1.41) 6.9  10–23
rs6838973 4q25 / PITX2 C / T 0.57 1.21 (1.16–1.26) 8.8  10–20 1.13 (1.09–1.17) 8.1  10–12
rs3807989 7q31 / CAV1 G / A 0.60 1.14 (1.10–1.19) 9.6  10–11 d d
rs10821415 9q22 / C9orf3 A / C 0.42 1.13 (1.08–1.18) 7.9  10–09 d d
rs10824026 10q22 / SYNPO2L A / G 0.84 1.17 (1.11–1.24) 1.7  10–08 d d
rs1152591 14q23 / SYNE2 A / G 0.48 1.13 (1.09–1.18) 6.2  10–10 d d
rs7164883 15q24 / HCN4 G / A 0.16 1.16 (1.10–1.22) 1.3  10–08 d d
rs2106261 16q22 / ZFHX3 T / C 0.18 1.24 (1.17–1.30) 3.2  10–16 d d
Analyses adjusted for age and sex (AFGen and BioBank Japan), and signiﬁcant principal components of ancestry (AFGen). *Discovery data from Ellinor et al. (12). ySingle nucleotide polymorphisms (SNPs)
representing distinct susceptibility signals derived from the 2 conditional analysis approaches.
AF ¼ atrial ﬁbrillation; CI ¼ conﬁdence interval; RR ¼ relative risk.
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1206signal tagged by rs1448818 is 135 kb centromeric of the top
signal at the locus, and is located 7 kb upstream of the
transcription factor PITX2. The signal tagged by rs4400058
is 11 kb telomeric of the top signal. Overall, the 10 kb
genomic regions ﬂanking each nonredundant SNP identiﬁedFigure 2
Regional Association Between Variants on Chromosome 4q
Top SNP at the Locus in the AFGen Sample
Associations between single nucleotide polymorphisms (SNPs) and atrial ﬁbrillation at the
top SNP (rs6817105) are displayed. Additional distinct susceptibility signals discovered
linkage disequilibrium between genetic variants in relation to rs6817105 is indicated by th
segment containing the associated nonredundant signals. Linkage data and recombination
from northern and western Europe).in our analysis were associated with a greater degree of
phylogenetic conservation than nucleotides at the remainder
of the 1 Mb locus on chromosome 4q25 (average conserva-
tion score 0.29  1.16 vs. 0.19  1.03, p < 0.001) (Online
Table 4).25 and Atrial Fibrillation After Adjustment for the
chromosome 4q25 locus (A) before and (B) after adjustment for the genotype of the
in this analysis are represented by purple circles and are labeled. The strength of
e color gradient as denoted in the legend. The region displayed is limited to a 310 kb
rates are derived from the HapMap phase II CEU panel (Utah residents with ancestry
AFGen BioBank Japan
SNP Adjusted
All Loci
SNP Adjusted
Chromosome
4q25 Onlyy
SNP Adjusted
All Loci
RR (95% CI) p Value Allele Frequency RR (95% CI) p Value RR (95% CI) p Value
1.12 (1.08–1.16) 1.6  10–8 0.02 d d 1.23 (0.91–1.67) 0.18
1.09 (1.06–1.13) 5.9  10–7 0.54 d d 1.12 (1.04–1.20) 2.0  10–3
1.12 (1.08–1.17) 3.1  10–8 0.25 0.98 (0.90–1.06) 0.56 0.97 (0.89–1.06) 0.49
1.60 (1.52–1.68) 1.2  10–80 0.47 1.92 (1.76–2.10) 5.1  10–48 1.90 (1.74–2.08) 5.4  10–46
1.31 (1.24–1.39) 4.1  10–20 0.22 1.43 (1.30–1.58) 1.8  10–12 1.42 (1.29–1.57) 6.2  10–12
1.13 (1.09–1.18) 7.1  10–12 0.48 1.12 (1.04–1.21) 2.2  10–3 1.11 (1.04–1.20) 3.9  10–3
1.05 (1.01–1.09) 6.3  10–3 0.66 d d 1.25 (1.16–1.35) 3.0  10–9
1.10 (1.06–1.15) 2.1  10–7 0.26 d d 1.08 (0.99–1.17) 0.07
1.16 (1.10–1.22) 4.9  10–9 0.60 d d 0.94 (0.88–1.01) 0.10
1.10 (1.06–1.14) 1.1  10–7 0.38 d d 1.02 (0.95–1.09) 0.63
1.13 (1.08–1.18) 3.1  10–7 0.11 d d 0.97 (0.86–1.08) 0.57
1.17 (1.12–1.23) 6.4  10–12 0.33 d d 1.28 (1.19–1.38) 7.0  10–11
Table 3 Continued
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1207We then constructed multimarker genetic risk scores
comprising the genome-wide signiﬁcant, nonredundant
SNPs at chromosome 4q25 listed in Table 3 and across all
AF loci to determine the composite associations between AF
risk alleles and AF. Both unweighted and weighted risk
scores were signiﬁcantly associated with AF (Table 4).
We observed a graded risk of AF that correlated with the
number of inherited AF risk alleles (Fig. 3, Online Fig. 2).
The most commonly observed number of AF risk alleles
across the 12 nonredundant SNPs (9,10) was observed in
25% of our sample. We observed 22% of individuals in our
sample that had greater than 10 estimated AF risk alleles
and that carried an increased age- and sex-adjusted risk for
AF, and 42% that had fewer than 9 AF risk alleles and that
carried a reduced risk for AF. By comparing the estimated
relative risks between those carrying the greatest and lowest
numbers of inherited AF risk alleles, we observed an esti-
mated 4-fold difference in AF risk captured by SNPs at theTable 4
Association Between Multimarker Risk S
and BioBank Japan Samples
Allele Score
AFGen
Beta (SE) p
Chromosome 4q25
Unweighted 0.21 (0.01) 2.6 
Weighted 0.98 (0.04) 1.4 
All AF loci
Unweighted 0.13 (<0.01) 9.6 
Weighted 0.86 (0.03) 9.0 
Beta coefﬁcients correspond to the estimated log-relative risk of atrial ﬁbrillati
nucleotide polymorphisms (SNPs) are listed in Table 3. All models adjusted fo
ancestry (AFGen). Weighting on the basis of regression estimate from conditio
4q25 or fromEllinor et al. (12) for other SNPs and applied as follows: 0.13*rs390
0.25*rs4400058_A, 0.11*rs6838973_C, 0.13*rs3807989_G, 0.12*rs10821
0.21*rs2106261_T.chromosome 4q25 locus, and 5-fold when considering all
independent loci.
We further sought to determine whether the observed
associations were generalizable beyond individuals of Eu-
ropean ancestry by examining AF-associated genetic variants
in 11,309 independent individuals of Japanese ancestry from
the BioBank Japan sample, 7,916 of whom had AF. We
observed that AF risk alleles for the most-signiﬁcant
SNPs in Europeans at 4 of the 9 loci associated with AF
were similarly associated with AF beyond genome-wide
signiﬁcance thresholds in Japanese after adjustment for one
another (Table 3). Overall, effect estimates were in the same
direction for 9 of the 12 tested variants in both European
and Japanese samples. Results were not substantially
changed in a subset in which adjustment for principal
components of ancestry was possible (Online Table 5). We
further observed that multimarker genetic scores were
signiﬁcantly associated with AF similar to those observed incores and AF in the AFGen Consortium
BioBank Japan
Value Beta (SE) p Value
10–73 0.26 (0.02) 2.7  10–38
10–107 1.19 (0.07) 2.6  10–58
10–107 0.15 (0.01) 2.0  10–37
10–148 0.99 (0.06) 7.6  10–63
on (AF) associated with each 1-unit increase in the score. Selected single
r age and sex (AFGen and BioBank Japan), and principal components of
nal analysis for single nucleotide polymorphisms (SNPs) on chromosome
3239_G, 0.17*rs6666258_C, 0.12*rs1448818_C, 0.48*rs6817105_C,
415_A, 0.16*rs10824026_A, 0.13*rs1152591_A, 0.15*rs7164883_G,
Figure 3 Graded Relative Risk of AF Stratiﬁed by the Number of Susceptibility Alleles in Europeans and Japanese
The risk of atrial ﬁbrillation (AF) is plotted according to the unweighted number of estimated distinct AF risk alleles, relative to that among individuals with the most common
number of estimated risk alleles for (A) chromosome 4q25, and (B) all genome-wide signiﬁcant AF susceptibility loci in individuals of European ancestry from the AFGen
Consortium. Replicated associations in the BioBank Japan sample are displayed in C and D, respectively. The distribution of risk alleles in the sample is displayed in the bar
graph to the left of the risk plots. The AF risk alleles are listed in Table 3.
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1208individuals of European ancestry (Table 4, Fig. 3, Online
Fig. 2). Among Japanese individuals, we observed an
approximately 5-fold gradient of AF risk when considering
the nonredundant markers on chromosome 4q25 identiﬁed
in Europeans, and 4-fold when considering all loci (Fig. 3).
We also examined the associations between each inde-
pendent AF-associated SNP with survival (n ¼ 25,007,
events ¼ 8,444) and survival free of major disease or mortality
(n ¼ 16,995, events ¼ 7,314) from prior genome-wide as-
sociation studies of aging (sample characteristics provided in
Online Table 6) (25). We did not observe any signiﬁcant
associations between each of the AF susceptibility SNPs and
either survival or survival free of major disease after adjust-
ment for multiple hypothesis testing with 12 SNPs (Online
Table 7). The most signiﬁcant association was with SNP
rs3903239 at the PRRX1 locus on chromosome 1q24 (rela-
tive risk for G [AF risk] allele: 1.04, 95% conﬁdence interval:
1.01 to 1.08, p ¼ 6.6  10–3 for survival; and relative risk:
1.04, 95% conﬁdence interval: 1.01 to 1.08, p ¼ 0.02) for
survival free of major disease.
Discussion
We employed 2 complementary methods to systematically
search for multiple AF susceptibility signals at 9 genome-
wide associated loci in a total of 64,683 individuals of
European ancestry, in which 7,171 individuals with AF wereincluded. Our ﬁndings demonstrate the presence of at least 4
distinct AF susceptibility signals in a large intergenic region
on chromosome 4q25. A multiallelic risk score comprising
12 AF susceptibility signals contributed to an estimated
5-fold age- and sex- adjusted gradient of AF risk. Whereas
about 22% of individuals had increased age- and sex-
adjusted risk of AF relative to those with the most com-
mon number of AF risk alleles, about 42% of individuals had
decreased AF risk on the basis of the number of AF risk
alleles that they carried. In an independent Japanese sample,
we observed nearly identical ﬁndings, suggesting that the
AF-genetic risk markers identiﬁed in our analysis may be
generalizable beyond populations of European ancestry.
We did not observe evidence for multiple genome-wide
signiﬁcant susceptibility signals at AF loci other than
chromosome 4q25. Our observations extend previous re-
ports about the relations between genetic markers and
AF risk, and underscore the complex nature of the AF
susceptibility locus on chromosome 4q25. Prior analyses
have reported independent markers on chromosome 4q25
related to AF (8,21), or post-operative AF (26). Indeed,
SNP rs4400058 is in perfect linkage with a previously
reported SNP rs10033464 at chromosome 4q25 in a
genome-wide association study of Icelanders (8). However,
rs10033464 has not been consistently associated with AF
in other analyses of individuals of European ancestry
(21,26,27).
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1209In the present analysis we observed a gradient of risk
that correlated with the number of AF risk alleles present.
We have observed that AF risk may vary substantially
between individuals with the same number of risk alleles in
a subset of the present AFGen sample (21), possibly due to
variable effects of particular SNPs, nonlinear interactions
between speciﬁc risk alleles, or differences in other clinical
or environmental AF risk factors. Few studies have
explored the utility of family history (6) or genotypic in-
formation (28,29) to discriminate AF risk. Future work
will be necessary to assess the best modeling strategy for
incorporating genetic markers into AF risk prediction ef-
forts, and to determine the best clinical setting in which to
utilize such tools.
Genetic associations that extend beyond single ancestral
groups may facilitate the identiﬁcation of true biological
variation underlying disease (30). Few prior analyses have
examined the relations between genetic factors and AF in
individuals of Japanese descent. A prior analysis from the
AFGen consortium related the top SNPs identiﬁed at
genome-wide susceptibility loci for AF to those in a sample
of 843 individuals with AF and 3,350 without from the
BioBank Japan sample, demonstrating marginal associations
between the top variants at the PRRX1, PITX2, CAV1, and
ZFHX3 loci. In aggregate, current and prior observations
provide support for a shared genetic susceptibility to AF in
individuals of European and Japanese descent, despite a
lower prevalence of AF among individuals of Japanese
ancestry (31,32).
Our ﬁndings implicate a broad AF susceptibility locus on
chromosome 4q25. The 4 susceptibility signals we identiﬁed
span 195 kb across an intergenic region on chromosome
4q25. The identiﬁed variants are upstream of PITX2, a
homeodomain transcription factor involved in determining
right-left cardiac symmetry, specifying pulmonary venous
myocardium, and suppressing formation of a default sinus
node in the left atrium (33–35). The expression of the Pitx2c
isoform is reduced in left atrial samples from humans with
AF as compared with those without a history of AF (36).
Knockout of the Pitx2c isoform in mice is associated with
increased susceptibility to pacing-induced atrial arrhythmias
and shortened atrial refractory periods (37), consistent with
electrical re-entry as a predominant mechanism of AF. Our
present ﬁndings implicate genetic variation within 7 kb of
PITX2 in the pathogenesis of AF, nearly 150 kb closer to
the gene than the top AF-associated signal at the locus in
the AFGen sample.
Our ﬁndings also implicate regulatory elements in
the pathogenesis of AF. Examination of phylogenetic con-
servation demonstrates that the identiﬁed AF susceptibility
signals cluster around conserved noncoding regions at
chromosome 4q25. Future work will be necessary to deter-
mine the functional role of these loci and the causal elements
tagged by the identiﬁed AF susceptibility SNPs. The iden-
tiﬁcation of individuals at high and low genetic risk of AF
may enhance the power of future sequencing efforts toidentify genetic variation at the chromosome 4q25 locus
underlying AF.
Our paper extends previous knowledge about the nature
of AF susceptibility regions. First, our analysis is the ﬁrst to
systematically assess for multiple susceptibility signals at all
genome-wide signiﬁcant AF susceptibility loci. Second, our
results provide the strongest evidence to date that multiple
susceptibility signals exist at chromosome 4q25; prior ana-
lyses did not rely on stringent genome-wide signiﬁcance
criterion to identify multiple signals at existing susceptibility
loci. Third, our analysis is the ﬁrst to implicate a distinct
susceptibility region within 7 kb of PITX2 in the patho-
genesis of AF, whereas prior data had not distinguished this
region from the peak association signal about 150 kb up-
stream of the gene. Fourth, our analysis extends previous
observations by demonstrating that the additive effects of
genetic variants tagging AF susceptibility signals in Euro-
peans, particularly at chromosome 4q25, transcend ancestry
and associate similarly with AF risk in Japanese individuals.
Study limitations. Our study must be interpreted in the
context of the study design. First, our analysis included only
individuals of European and Japanese ancestry, and therefore
it is not clear whether our ﬁndings are generalizable to in-
dividuals of other ancestral backgrounds. Second, we cannot
exclude the possibility that our stringent signiﬁcance
threshold excluded other true independent susceptibility
signals with heterogeneous associations across cohorts.
Indeed, we previously identiﬁed a genetic variant on chro-
mosome 4q25 (rs17570669) that was independently associ-
ated with AF in prior work, and which was nominally
associated with AF in the present analysis, but not at our
predeﬁned genome-wide signiﬁcance threshold. Whether
this is due to poor imputation of the SNP genotypes, het-
erogeneity in the association across study samples, or true
absence of association when considering other more signiﬁ-
cantly associated SNPs is not clear. Third, as with any SNP-
based genetic association study, the discovered SNPs are
likely proxies for causal functional elements underlying AF
rather than the causal variants themselves. Fourth, we
assumed that the risk of AF associated with each allele is
multiplicative and that the effects for each SNP contribute to
AF risk additively. Our analysis does not address the po-
tential for interactions between SNPs, or between SNPs and
environmental factors, which may associate with AF risk.
Conclusions
We systematically examined 9 genome-wide signiﬁcant AF
susceptibility loci for additional independent signals. We
identiﬁed at least 4 distinct signals on chromosome 4q25
upstream of PITX2, which implicate an arrhythmia sus-
ceptibility region at this locus that spans about 195 kb. In
aggregate, the number of genetic risk markers for AF
correlated with a marked gradient of AF risk in both samples
of European and Japanese descent, and identiﬁed individuals
both at increased as well as at decreased risk of AF relative to
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1210those with the most common number of risk markers. Our
observations underscore the biological complexity of the
chromosome 4q25 locus and importance of the region in AF
pathogenesis.
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